Expression of vascular endothelial growth factor in canine oral malignant melanoma

Veterinary and Comparative Oncology

Volumn 5, Issue 4, 2007, Pages 208-218

  Taylor, K H ^a,b   Smith, A N ^a   Higginbotham, M ^a   Schwartz, D D ^a   Carpenter, D M ^a   Whitley, E M ^a  

^a AUBURN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS;

EID: 65749099035     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2007.00130.x     Document Type: Article

References (39)

1. Modiano JF, Ritt MG and Wojcieszyn J. The molecular basis of canine melanoma: Pathogenesis and trends in diagnosis and therapy. Journal of Veterinary Internal Medicine 1999; 13: 163-174.
2. Sulaimon SS and Kitchell BE. Canine melanoma: Combating a destructive and deadly tumor. Veterinary Medicine 2001; 96: 931-941.
3. Withrow SJ. Cancer of the gastrointestinal tract. In: Small Animal Clinical Oncology, SJ Withrow and EG MacEwen, eds., Philadelphia, Saunders, 2001: 305-317.
4. Proulx DR, Ruslander DM, Dodge RK, Hauck ML, Williams LE, Horn B, Price GS and Thrall DE. A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Veterinary Radiology and Ultrasound 2003; 44: 352-359.
5. Rassnick KM, Ruslander DM, Cotter SM, Al-Sarraf R, Bruyette DS, Gamblin RM, Meleo KA and Moore AS. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). Journal of the American Veterinary Medical Association 2001; 218: 1444-1448.
6. Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM, Leung C, Liao J, Riviere I, Sadelain M, Hohenhaus AE, Gregor P, Houghton AN, Perales MA and Wolchok JD. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006; 24: 4582-4585.
7. Alexander AN, Huelsmeyer MK, Mitzey A, Dubielzig RR, Kurzman ID, MacEwen EG and Vail DM. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunology and Immunotherapy 2006; 55: 433-442.
8. Sulaimon SS and Kitchell BE. The basic biology of malignant melanoma: molecular mechanisms of disease progression and comparative aspects. Journal of Veterinary Internal Medicine 2003; 17: 760-772.
9. Miller AJ and Mihm MC. Melanoma. New England Journal of Medicine 2006; 355: 51-65.
10. Srivastava A, Ralhan R and Kaur J. Angiogenesis in cutaneous melanoma: pathogenesis and clinical implications. Microscopy Research and Technique 2003; 60: 208-224.
11. Sreit M and Detmar M. Angiogenesis, lymphangiogenesis and melanoma metastasis. Oncogene 2003; 22: 3172-3179.
12. Ugurel S, Rappl G, Tilgen W and Reinhold U. Increased serum concentrations of angiogenic factors in malignant melanoma patients correlated with tumor progression and survival. Journal of Clinical Oncology 2001; 19: 577-583.
13. Rofstad EK and Halsør EF. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Research 2000; 60: 4932-4938.
14. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson J, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ESE, Curry B, Richmond GHP and Wadsworth PF. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Research 2002; 62: 4645-4655.
15. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. Journal of Molecular Medicine 1999; 77: 527-543.
16. Pelletier F, Bermont L, Puzenat E, Blanc D, Cairey-Remonnay S, Mougin C, Laurent R, Humbert P and Aubin F. Circulating vascular endothelial growth factor in cutaneous malignant melanoma. British Journal of Dermatology 2005; 152: 685-689.
17. Graeven U, Fiedler W, Karpinski S, Ergün S, Kilic N, Rodeck U, Schmiegel W and Hossfeld DK. Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. Journal of Cancer Research and Clinical Oncology 1999; 125: 621-629.
18. Rawlings NG, Simko E, Bebchuk T, Caldwell SJ and Singh B. Localization of integrin alpha(v)beta3 and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in cutaneous and oral melanomas of dog. Histology and Histopathology 2003; 18: 819-826.
19. Graeven U, Rodeck U, Karpinski S, Jost M, Philippou S and Schmiegel W. Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Research 2001; 61: 7282-7290.
20. Scheidegger P, Weiglhofer W, Suarez S, Kaser-Hotz B, Steiner R, Ballmer-Hofer K and Jaussi R. Vascular endothelial growth factor (VEGF) and its receptors in tumor-bearing dogs. Biological Chemistry 1999; 380: 1449-1454.
21. Plum SM, Holaday W, Ruiz A, Madsen JW, Fogler WE and Fortier AH. Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. Vaccine 2000; 19: 1294-1303.
22. Clifford CA, Hughes D, Beal MW, Mackin AJ, Henry CJ, Shofer FS and Screnmo KU. Plasma vascular endothelial growth factor concentrations in healthy dogs and dogs with hemangiosarcoma. Journal of Veterinary Internal Medicine 2001; 15: 131-135.
23. Mohammed SI, Craig BA, Mutsaers AJ, Glickman NW, Snyder PW, deGortari AE, Schlittler DL, Coffman KT, Bonney PL and Knapp DW. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Molecular Cancer Therapeutics 2003; 2: 183-188.
24. Wergin MC and Kaser-Hotz B. Plasma vascular endothelial growth factor (VEGF) measured in seventy dogs with spontaneously occurring tumours. In Vivo 2004; 18: 15-20.
25. Gentilini F, Calzolari C, Turba ME, Agnoli C, Fava D, Forni M and Bergamini PF. Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs. Leukemia Research 2005; 29: 1263-1269.
26. Allen DK, Walters DJ, Knapp DW and Kuczek T. High urine concentrations of basic fibroblast growth factor in dogs with bladder cancer. Journal of Veterinary Internal Medicine 1996; 10: 231-234.
27. Lazarous DF, Shou M, Stiber JA, Hodge E, Thirumurti V, Goncalves L and Unger EF. Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: Effect on myocardial angiogenesis. Cardiovascular Research 1999; 44: 294-302.
28. Gu JW, Elam J, Sartin A, Li W, Roach R and Adair TH. Moderate levels of ethanol induce expression of vascular endothelial growth factor and stimulate angiogenesis. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2001; 282: R365-R372.
29. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clinical Chemistry 2001; 47: 617-623.
30. Restucci B, Papparella S, Maiolino P and De Vico G. Expression of vascular endothelial growth factor in canine mammary tumors. Veterinary Pathology 2002; 39: 488-493.
31. Maiolino P, De Vico G and Restucci B. Expression of vascular endothelial growth factor in basal cell tumours and in squamous cell carcinomas of canine skin. Journal of Comparative Pathology 2000; 123: 141-145.
32. Millanta F, Lazzeri G, Vannozzi I, Viacava P and Poli A. Correlation of vascular endothelial growth factor expression to overall survival in feline invasive mammary carcinomas. Veterinary Pathology 2002; 39: 690-696.
33. Gerardi JG, Colitz CM II, Dubielzig RR and Davidson MG. Immunohistochemical analysis of lens epithelial-derived membranes following cataract extraction in the dog. Veterinary Ophthalmology 1999; 2: 163-168.
34. Restucci B, Maiolino P, Paciello O, Martano M, De Vico G and Papparella S. Evaluation of angiogenesis in canine seminomas by quantitative immunohistochemistry. Journal of Comparative Pathology 2003; 128: 252-259.
35. Platt SR, Sease TJ, Adams V, Wieczorek L, Miller J, Adamo F and Long S. Vascular endothelial growth factor expression in canine intracranial meningiomas and association with patient survival. Journal of Veterinary Internal Medicine 2006; 20: 663-668.
36. Salgado R, Benoy I, Bogers J, Weytjens R, Vermeulen P, Dirix L and Van Marck E. Platelets and vascular endothelial growth factor (VEGF): A morphological and functional study. Angiogenesis 2001; 4: 37-43.
37. Lee JK, Hong YJ, Han CJ, Hwang DY and Hong SI. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen? International Journal of Oncology 2000; 17: 149-152.
38. MacEwen EG, Patnaik AK, Harvey HJ, Hayes AA and Matus R. Canine oral melanoma: Comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Investigation 1986; 4: 397-402.
39. MacEwen EG, Kurzman ID, Vail DM, Dubielzig RR, Everlith K, Madewell BR, Rodriguez CO, Phillips B, Zwahlen CH, Obradovich J, Rosenthal RC, Fox LE, Rosenberg M, Henry C and Fidel J. Adjuvant therapy for melanoma in dogs: Results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clinical Cancer Research 1999; 5: 4249-4258.